Erratum: Pharmacodynamic properties of methotrexate and Aminotrexate TM during weekly therapy (Cancer Chemotherapy and Pharmacology (2005) DOI: http://dx.doi.org/10.1007/s00280-005-0115-3);Pharmacodynamic properties of methotrexate and Aminotrexate™ during weekly therapy

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 826-834

  Cole, Peter D ^a   Alcaraz, María José ^b   Smith, Angela K ^a   Tan, John ^c   Kamen, Barton A ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Acute lymphoblastic leukemia; Aminopterin; Methotrexate; Neurotoxicity; Polyglutamates; Rheumatoid arthritis

Indexed keywords

AMINOPTERIN; AMINOTREXATE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; POLYGLUTAMIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REGIMEN; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; KIDNEY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STEADY STATE; TESTIS;

EID: 33645750806     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0234-5     Document Type: Erratum

References (49)

1. Angelis-Stoforidis P, Vajda FJ, Christophidis N (1999) Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 17:313
2. Balinska M, Galivan J, Coward JK (1981) Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res 41:2751
3. Bertino JR (1963) The mechanism of action of the folate antagonists in man. Cancer Res 23:1286
4. Bettachi CJ, Kamen BA, Cush JJ (1999) Post-methotrexate (MTX) CNS toxicity: symptom reduction with dextromethorphan. Arthritis Rheuma 42:S236
5. Bleyer WA, Dedrick RL (1977) Clinical pharmacology of intrathecal methotrexate I Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703
6. Bleyer WA, Nelson JA, Kamen BA (1997) Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 19:530
7. Cole PD, Drachtman RA, Masterson M, Shenkerman A, Smith AK, Makori B, Kamen BA (2004) Aminopterin can replace methotrexate for children with newly diagnosed acute lymphoblastic leukemia without excessive toxicity [Abstract#1950]. Blood 104:538a
8. da Costa M, Iqbal MP (1981) The transport and accumulation of methotrexate in human erythrocytes. Cancer 48:2427
9. Dameshek W, Freedman MH, Steinberg L (1950) Folic acid antagonists in the treatment of acute and subacute leukemia. Blood 5:898
10. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis & Rheumatism 50:2766
11. Dervieux T, Furst D, Orentas Lein D, Capps R, Smith K, Caldwell J, Kremer J (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis ard.2004.033399
12. Ercikan-Abali EA, Waltham MC, Dicker AP, Schweitzer BI, Gritsman H, Banerjee D, Bertino JR (1996) Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. Mol Pharmacol 49:430
13. Farber S, Toch R, Sears EM, Pinkel D (1956) Advances in chemotherapy of cancer in man. Adv Cancer Res 4:1-71
14. Freemantle SJ, Moran RG (1997) Transcription of the human folylpoly-gamma-glutamate synthetase gene. J Biol Chem 272:25373
15. George S, Cichowicz DJ, Shane B (1987) Mammalian folylpoly-gamma- glutamate synthetase 3 Specificity for folate analogues. Biochemistry 26:522
16. Graham ML, Shuster JJ, Kamen BA, Cheo DL, Harrison MP, Leventhal BG, Pullen DJ, Whitehead VM (1992) Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 31:217
17. Harvey JW (1989) Erythrocyte Metabolism. In: Kaneko JJ (ed) Clinical biochemistry of domestic animals, 4th edn. Academic, San Diego, pp 196
18. Hendel J, Nyfors A (1984) Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol 27:607
19. Jolivet J, Chabner BA (1983) Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest 72:773
20. Kamen BA, Nylen PA, Camitta BM, Bertino JR (1981) Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 49:355
21. Kamen BA, Takach PL, Vatev R, Caston JD (1976) A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 70:54
22. Krakower GR, Kamen BA (1983) In situ methotrexate polyglutamate formation in rat tissues. J Pharmacol Exp Ther 227:633
23. Krakower GR, Kamen BA (1984) The reticulocytic rat: a model for analysis of methotrexate polyglutamate dynamics in situ. J Pharmacol Exp Thera 231:43
24. Kristensen K, Nielsen S, Karup Pedersen F, Zak M (2000) Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis. Scand J Rheumatol 29:187
25. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL (1988) Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res 48:1481
26. Kumar P, Kisliuk RL, Gaumont Y, Nair MG, Baugh CM, Kaufman BT (1986) Interaction of polyglutamyl derivatives of methotrexate, 10-deazaaminopterin, and dihydrofolate with dihydrofolate reductase. Cancer Res 46:5020
27. Leclerc GJ, Barredo JC (2001) Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clinical Cancer Research 7:942
28. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia:an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol 16:1712
29. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo A rationale for high-dose methotrexate. J Clin Invest 97:73
30. Osborn MJ, Huennekens FM (1958) Enzymatic reduction of dihydrofolic acid. J Biol Chem 233:969
31. Posadas I, Terencio MC, Guillen I, Ferrandiz ML, Coloma J, Paya M, Alcaraz MJ (2000) Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol 361:98
32. Quinn CT, Kamen BA (1996) A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med 44:522
33. Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA (1998) Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458
34. Rosenblatt DS, Whitehead VM (1983) Methotrexate polyglutamates in cultured human cells. Adv Exp Med Biol 163: 275
35. Samuels LL, Moccio DM, Sirotnak FM (1985) Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro. Cancer Res 45:1488
36. Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Makipernaa A, Rosthoj S, Szumlanski C, Sorensen TM, Weinshilboum R (2003) Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 21:1332
37. Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13:345
38. Schmiegelow K, Schroder H, Pulczynska MK, Hejl M (1989) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother Pharmacol 25:65
39. Schmiegelow K, Schroder H, Schmiegelow M (1994) Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters?. Cancer Chemother Pharmacol 34:209
40. Schroder H (1990) In vivo methotrexate kinetics and metabolism in human hematopoietic cells Clinical significance of methotrexate concentrations in erythrocytes. Danish Med Bull 37:22
41. Schweitzer BI, Srimatkandada S, Gritsman H, Sheridan R, Venkataraghavan R, Bertino JR (1989) Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. J Biol Chem 264:20786
42. Sirotnak FM, Donsbach RC (1972) Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell. Cancer Res 32:2120
43. Smith A, Hum M, Winick NJ, Kamen BA (1996) A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2:69
44. Turner FB, Andreassi JL II, Ferguson J, Titus S, Tse A, Taylor SM, Moran RG (1999) Tissue-specific expression of functional isoforms of mouse folypoly-gamma-glutamate synthetase: a basis for targeting folate antimetabolites. Cancer Res 59:6074
45. Turner FB, Taylor SM, Moran RG (2000) Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 275:35960
46. Vezmar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92
47. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D (1990) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 76:44
48. Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, Buchanan GR, Kamen BA (1996) Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 14:2803
49. Winick NJ, Kamen BA, Balis FM, Holcenberg J, Lester CM, Poplack DG (1987) Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Deliv 4:25